<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="730">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04409483</url>
  </required_header>
  <id_info>
    <org_study_id>Trascov</org_study_id>
    <nct_id>NCT04409483</nct_id>
  </id_info>
  <brief_title>Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger</brief_title>
  <acronym>TRASCOV</acronym>
  <official_title>Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epicentre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Abdou Moumouni</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche Médicale et Sanitaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Public Health, Republic of Niger</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epicentre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether lopinavir/ritonavir (or eventually other
      antiviral drugs) is effective at reducing the rate of hospitalization among confirmed
      COVID-19 cases treated as outpatients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and potential risks, all patients who meet all
      eligibility criteria and who give written informed consent will be randomized to receive
      standard care or standard care plus lopinavir/ritonavir (400mg/100mg twice daily for 14
      days). Participants will receive daily visits from study staff for 15 days and be followed
      for a total of 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Epidemic dynamics
  </why_stopped>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization or death</measure>
    <time_frame>15 days following randomization</time_frame>
    <description>Hospitalization associated with desaturation (SpO2 ≤92%) or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>15 days following randomization</time_frame>
    <description>Death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>28 days following randomization</time_frame>
    <description>Death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to hospitalization</measure>
    <time_frame>28 days following randomization</time_frame>
    <description>Length of time between randomization and hospitalization associated with desaturation (SpO2 ≤92%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>28 days following randomization</time_frame>
    <description>Total duration of hospitalization associated with desaturation (SpO2 ≤92%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to intensive care</measure>
    <time_frame>28 days following randomization</time_frame>
    <description>Proportion of participants admitted to an intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days following randomization</time_frame>
    <description>Proportion of participants having an adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>28 days following randomization</time_frame>
    <description>Proportion of participants having a serious adverse event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard care for COVID-19 according to the national guidelines of Niger</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care plus lopinavir/ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard care for COVID-19 according to the national guidelines of Niger plus lopinavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir-Ritonavir Drug Combination</intervention_name>
    <description>400mg/100mg taken orally twice daily for 14 days.</description>
    <arm_group_label>Standard Care plus lopinavir/ritonavir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily</description>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_label>Standard Care plus lopinavir/ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspect, probable or confirmed case of COVID-19

          -  Men and women aged ≥12 years, including pregnant and breastfeeding women

          -  SpO2 ≥93% on room air

          -  Signature of informed consent form

        Exclusion Criteria:

          -  Medical indication for hospitalization at the time of enrolment

          -  Severe chronic liver disease

          -  Known infection with HIV

          -  Known allergy or severe intolerance to lopinavir/ritonavir

          -  Absolute contra-indication to lopinavir/ritonavir, including concomitant therapy with
             a medication whose metabolism is dependent on isoform CPY3A with a narrow therapeutic
             window (e.g., amiodarone, colchicine, simvastatin, lovastatin, etc.)

          -  Treatment with an antiviral medication in the 28 days prior to enrolment

          -  Dementia or other condition that interferes with active participation in data
             collection and obtaining informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca F Grais</last_name>
    <role>Study Director</role>
    <affiliation>Epicentre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Adehossi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Général de Référence de Niamey</affiliation>
  </overall_official>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2020</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified patient data will be shared with local and international authorities.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will become fully accessible after primary publication of results.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

